Indaptus Therapeutics, Inc. filed 5 current reports with the SEC under Item 5.02, which covers directors and officers leaving or being appointed, the latest on 2026-09-04. Between them they name 4 people, with 6 appointments and 3 departures. Each change below is quoted from the filing and linked to it.
Every change, newest first
Departing: Tim Ruan
On September 2, 2026, Tim Ruan notified the Board of Directors (the " Board ") of Indaptus Therapeutics, Inc. (the " Company ") of his resignation from the Board, effective immediately.
Appointed: Walt A. Linscott, Chief Operating Officer, effective 2026-06-01
Effective as of June 1, 2026, Mr. Walt A. Linscott, Esq. resigned as the Chief Operating Officer of the Company, and, pursuant to a consulting agreement with the Company dated June 1, 2026, will serve as a consultant for the Company.
Appointed: Tim Ruan, Director, effective 2026-04-22
On April 17, 2026, the Board of Directors (the " Board ") of Indaptus Therapeutics, Inc. (the " Company ") appointed Mr. Tim Ruan and Dr. Johnny Fox Arrowsmith as independent directors of the Board, effective April 22, 2026.
Appointed: Tim Ruan
Committee Appointments Effective as of their respective appointment dates to the Board: Mr. Ruan was appointed to serve as a member of the Audit Committee of the Board.
Departing: Matthew McMurdo, Director
On April 22, 2026, Matthew McMurdo resigned as a director of the Company.
Appointed: Tim Ruan, Director, effective 2026-04-22
On April 17, 2026, the Board of Directors (the " Board ") of Indaptus Therapeutics, Inc. (the " Company ") appointed Mr. Tim Ruan and Dr. Yi Zhang as independent directors of the Board, effective April 22, 2026.
Appointed: Tim Ruan
Committee Appointments Effective as of their respective appointment dates to the Board: Mr. Ruan was appointed to serve as a member of the Audit Committee of the Board.
Departing: Matthew McMurdo, Director
On April 22, 2026, Matthew McMurdo resigned as a director of the Company.
Appointed: Qinglai Lu, Director, effective 2026-04-08
On March 31, 2026, the Board of Directors appointed Qinglai Lu as a member of the Board of Directors, effective April 8, 2026.
Find people with the same kind of experience as the Chief Operating Officer at Indaptus Therapeutics, Inc., with the record behind each one.
Find candidates like Chief Operating Officer at Indaptus Therapeutics, Inc.New leaders review vendors and budgets in their first months. Get an alert the next time Indaptus Therapeutics, Inc. is in the news or changes leadership.
Get an alert when Indaptus Therapeutics, Inc. changes leadershipTools for this story
Each opens in a new tab, filled in for Indaptus Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.